CYP1A2 polymorphisms are associated with lung cancer

CYP1A2-T2467delT polymorphism has an important role in lung carcinogenesis, especially SCC, among smokers.

This study suggests that single nucleotide polymorphisms of CYP1A2 could be considered as promising biomarkers in the aetiology of lung adenocarcinoma in smokers

CYP1A2 genotypes interact with environmental risk factors in enhancing the risk to squamous cell lung carcinoma.

results demonstrate that CYP1A2 variant C of -163A/C, even independent of smoking exposure, may increase lung cancer risk, whereas variant delT of -2467 T/delT interacts with cigarette smoking to modify lung cancer risk in males

Several CYP1A2 haplotypes containing the -2467delT variant were associated with lower lung cancer risk, however, they did not correlate with significant changes in CYP1A2 metabolic activity toward caffeine.

rs3569413 polymorphism of the CYP1A2 gene is associated with an increased risk of lung cancer.

CYP1A2 -163C>A polymorphism is associated with lung cancer risk.

this meta-analysis indicates that the CYP1A2 rs762551 polymorphism is linked to an increased lung cancer risk in Caucasians

Results show high prevalence of functional CYP1A2*1F allele in Hungarian people suggesting an increased chance for breast, lung and ovarian cancer, mostly in case of susceptible exposure.

CYP1A2 polymorphisms are associated with lung cancer and bladder cancer risk in Caucasians. [Meta-analysis]

CYP1A2 Polymorphisms are associated with lung cancer.

findings indicated that the -3860 G > A polymorphism in CYP1A2 might not be a risk factor for lung cancer [meta-analysis]

Results suggest that CYP4503A4/1A2 phenotyping is unlikely to substitute therapeutic drug monitoring of erlotinib in patients with advanced non-small cell lung cancer.